Ph.D., Chair, Department of Genetics, Stanford University
Biography
Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and multiomics, and one of the major participants of the ENCODE project. His laboratory was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites), and a high diversity of transcription factor binding occurs both between and within species. He launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person, and his laboratory pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health.
Session Abstract – PMWC 2022 Silicon Valley
Track 5 - June 28 2.15 P.M.-3.00 P.M.
Panel
Session Abstract – PMWC 2022 Silicon Valley
Track 5 - June 28 2.15 P.M.-3.00 P.M.
Track Chair:
Keith Yamamoto, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support
Sessions:
- Realizing the Promise of Precision Medicine Using Real-world Evidence (PANEL)
Session Chair: Atul Butte, UCSF
- Nancy A. Dreyer, IQVIA
- Mark Laabs, RCRF
- Rhonda Cooper-DeHoff, University of Florida
- Chris Boone, Abbvie - Opportunities and Challenges in Using Real World Data (RWD) (PANEL)
Session Chair: Vivek Rudrapatna, UCSF
- Mark Hoffman, Childrens Mercy Hospital
- Ida Sim, UCSF
- Julian Hong, UCSF - How Are Patient Data Revolutionizing Precision Medicine? (PANEL)
Session Chair: Clara Lajonchere, UCLA
- Sharon Terry, Genetic Alliance
- Farid Vij, Invitae
- Latha Palaniappan, Stanford - Government Partnerships: California Initiative to Advance Precision Medicine
Session Chair: Julianne McCall, California Initiative to Advance Precision Medicine
- William Kim, UCSD
- Mike Snyder, Stanford - Leveraging RWE to Create Value (PANEL)
Session Chair: Latha Palaniappan, Stanford
- Brook Schroeder, Illumina
- Suzanne Belinson, Tempus
- Stacey Dacosta Byfield, Optum Genomics - Computational Social Choice Theory's Impact on the Collection and Understanding of RWD
- Ian Terry, LunaDNA - PMWC Showcase
- Chris Williams, MMRF
- Jason Crites, Assurance Health Data
